Conjugation of Anticancer Drugs Through Endogenous Monoclonal Antibody Cysteine Residues
Authors:
- David L. MeyerDMDavid L. Meyer
- Jocelyn R. SetterJSJocelyn R. Setter
- Peter D. SenterPSPeter D. Senter
- 1 January 2012
- book chapter
- Published by Elsevier
- Vol. 502, 123-138
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Optimizing Therapeutic Antibody FunctionBioDrugs, 2011
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast CancerClinical Cancer Research, 2010
- Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid ConjugatesBioconjugate Chemistry, 2009
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic DrugsAccounts of Chemical Research, 2007
- Perspective – FcRn transports albumin: relevance to immunology and medicineTrends in Immunology, 2006
- Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicityBioconjugate Chemistry, 2005
- Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug ConjugateClinical Cancer Research, 2004
- Development of potent monoclonal antibody auristatin conjugates for cancer therapyNature Biotechnology, 2003
- Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkagesBioorganic & Medicinal Chemistry Letters, 2002